Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
ALLO-715 consists of a preparation of allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets BCMA, with disruption of TCR alpha and CD52 to potentially reduce risk of GVHD and resistance to CD52 antibody therapy, which may enhance cytotoxicity against tumor cells expressing BCMA (Blood (2018) 132 (Supplement 1): 591).
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|ALLO-647 + ALLO-715||ALLO-647 ALLO-715||0||1|
|ALLO-647 + ALLO-715 + Cyclophosphamide + Fludarabine||ALLO-647 ALLO-715 Cyclophosphamide Fludarabine||0||1|